Ensweet key facts
as of Oct 2026- Developer of a telemedicine-based rehabilitation system designed for remote therapeutic care intended to extend access to structured cardiac recovery programs.
- Ensweet is valued at approximately $8.3M as of Oct 2026 (last reported valuation).
- It has raised $5.7M; the latest was Later Stage VC ($3.1M) in Mar 2025.
- Notable investors include XAnge, 50 Partners, IRD Invest, AG2R La Mondiale, Angels Santé — 12 tracked in total.
- Status: Privately Held (backing).
Ensweet's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Ensweet: the Monday email on marks, rounds and moves
Ensweet funding rounds
No funding rounds for Ensweet are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ensweet
12+Ensweet valuation
Ensweet's last reported valuation was $8.3 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Ensweet investors
12 investors are on record for Ensweet, including XAnge, 50 Partners, IRD Invest and AG2R La Mondiale.
About Ensweet
Developer of a telemedicine-based rehabilitation system designed for remote therapeutic care intended to extend access to structured cardiac recovery programs. The company's platform includes integrated heart-rate monitoring, physical-activity guidance tools, remote supervision interfaces for healthcare teams, and home-based rehabilitation workflows, enabling patients with cardiac conditions to receive accessible, continuous, and location-independent rehabilitation support while maintaining coordinated communication with multidisciplinary caregivers.
- Sector
- Healthcare
- HQ
- Lille, France
- Founded
- 2020
- Employees
- 18
- Website
- ensweet.fr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.